TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Option Exercise | M | 0.00 | 5,712 | 0 | 0 | |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | See "Remarks" below | Buy | M | 0.00 | 5,712 | 0 | 111,324 | 105.6 K to 111.3 K (+5.41 %) |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 5,355 | 0 | 0 | |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 11.12 | 2,098 | 23,336 | 103,294 | 105.4 K to 103.3 K (-1.99 %) |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 5,355 | 0 | 105,392 | 100 K to 105.4 K (+5.35 %) |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Option Exercise | M | 0.00 | 3,926 | 0 | 0 | |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Sell | S | 11.13 | 2,079 | 23,135 | 39,572 | 41.7 K to 39.6 K (-4.99 %) |
| Feb 17 2021 | TEVA | TEVA PHARMACEUTICA ... | Drape Eric | Executive VP Global ... | Buy | M | 0.00 | 3,926 | 0 | 41,651 | 37.7 K to 41.7 K (+10.41 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | A | 0.00 | 37,884 | 0 | 37,884 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 12,538 | 0 | 12,538 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 12.69 | 52,774 | 669,940 | 2,974 | 55.7 K to 3 K (-94.67 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 12.69 | 12,538 | 159,164 | 55,748 | 68.3 K to 55.7 K (-18.36 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Grant | A | 0.00 | 52,774 | 0 | 68,286 | 15.5 K to 68.3 K (+340.21 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 12,538 | 0 | 15,512 | 3 K to 15.5 K (+421.59 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Option Exercise | M | 0.00 | 26,867 | 0 | 26,867 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Grant | A | 0.00 | 226,173 | 0 | 735,834 | 509.7 K to 735.8 K (+44.38 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Schultz Kare | President and CEO | Buy | M | 0.00 | 26,867 | 0 | 509,661 | 482.8 K to 509.7 K (+5.56 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 16,120 | 0 | 16,121 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 12.69 | 16,720 | 212,252 | 78,146 | 94.9 K to 78.1 K (-17.62 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 12.69 | 3,974 | 50,448 | 94,866 | 98.8 K to 94.9 K (-4.02 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Grant | A | 0.00 | 67,852 | 0 | 98,840 | 31 K to 98.8 K (+218.96 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 16,120 | 0 | 30,988 | 14.9 K to 31 K (+108.42 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Option Exercise | M | 0.00 | 11,941 | 0 | 11,941 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 12.72 | 17,480 | 222,361 | 60,410 | 77.9 K to 60.4 K (-22.44 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Sell | S | 12.72 | 4,155 | 52,855 | 77,890 | 82 K to 77.9 K (-5.06 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Grant | A | 0.00 | 50,260 | 0 | 82,045 | 31.8 K to 82 K (+158.12 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, International ... | Buy | M | 0.00 | 11,941 | 0 | 31,785 | 19.8 K to 31.8 K (+60.17 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 13,135 | 0 | 13,135 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 12.69 | 23,962 | 304,186 | 59,404 | 83.4 K to 59.4 K (-28.74 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 12.69 | 5,695 | 72,295 | 83,366 | 89.1 K to 83.4 K (-6.39 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Grant | A | 0.00 | 55,287 | 0 | 89,061 | 33.8 K to 89.1 K (+163.70 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 13,135 | 0 | 33,774 | 20.6 K to 33.8 K (+63.64 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 13,135 | 0 | 13,135 | |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 12.72 | 55,287 | 703,300 | 10,765 | 66.1 K to 10.8 K (-83.70 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 12.72 | 13,135 | 167,089 | 66,052 | 79.2 K to 66.1 K (-16.59 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Grant | A | 0.00 | 55,287 | 0 | 79,187 | 23.9 K to 79.2 K (+231.33 %) |
| Feb 11 2021 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 13,135 | 0 | 23,900 | 10.8 K to 23.9 K (+122.02 %) |